R&D Update on April 10, 2014 in New York
Innate Pharma will update investors and analysts on its pipeline and strategy The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II...
Monalizumab
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
Novo Nordisk to reinforce its equity stake in Innate Pharma Marseille, France and Bagsværd, Denmark, 5 February 2014 Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready NKG2A is a NK...
Monalizumab
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S
IPH2201 is the third monoclonal antibody developed in collaboration with Novo Nordisk A/S expected to enter clinical trials Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces...